-
2023-505925-15-00
7
2024-03-21
Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined
-
2022-501408-81-01
4
2024-03-04
Covid-19
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2022-502351-60-00
4
2024-02-22
Patients having a HER2-amplified metastatic breast cancer with evoluti
-
2023-504366-36-00
5
2024-02-17
de novo acute respiratory failure
-
2023-504146-60-00
10
2024-02-07
lymphatic malformations associated with PIK3CA mutation
-
2022-500862-93-00
5
2024-02-01
Pulmonary Hypertension
-
2023-505889-29-01
4
2024-02-01
Patients with unresectable locally advanced or metastatic pancreatic c
-
2022-502046-28-00
5
2023-12-22
HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
-
2024-514101-65-00
4
2023-12-21
Multiple Myeloma
-
2022-500743-20-00
4
2023-12-19
Metastatic HER2+ Breast cancer
-
2022-502273-42-00
5
2023-11-08
Glaucoma
-
2022-502154-13-00
5
2023-10-27
Patients with well to moderately differentiated neuroendocrine tumors
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2022-501057-36-00
5
2023-10-24
ANCA-associated vasculitis
-
2022-501904-83-00
7
2023-09-11
Ovarian Cancer
-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2022-500974-33-00
5
2023-08-12
acute venous thromboembolism event
-
2022-500933-10-00
11
2023-08-02
Preeclampsia during pregnancy
-
2022-500587-35-01
5
2023-07-06
Stroke
-
2022-500967-11-00
5
2023-07-06
Previously Untreated Metastatic or Unresectable Melanoma
-
2024-513811-29-00
5
2023-07-03
Cardiogenic Shock
-
2024-514952-34-00
5
2023-06-23
Catheter related bloodstream infections due to Staphylococcus aureus
-
2022-501710-62-02
6
2023-06-07
Peripheral T-cell lymphoma (PTCL)